scholarly journals Risk Factors and Prevalence ofHelicobacter pyloriInfection in Persistent High Incidence Area of Gastric Carcinoma in Yangzhong City

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
Yangchun Zhu ◽  
Xiaoying Zhou ◽  
Junbei Wu ◽  
Jing Su ◽  
Guoxin Zhang
Keyword(s):  
Risk Factors ◽  
Peptic Ulcer ◽  
Breath Test ◽  
Multivariate Logistic Regression Analysis ◽  
Urea Breath Test ◽  
Epidemiologic Survey ◽  
Significant Difference ◽  
High Prevalence ◽  
13C Urea Breath Test ◽  
H Pylori

Aim. The aim of this study was to investigate the prevalence and risk factors ofH. pyloriinfection in areas with high prevalence of gastric cancer in Jiangsu Province, China.Methods. A prospective epidemiologic survey ofH. pyloriinfection was accomplished in a natural population of 5417 individuals in Yangzhong city. Questionnaires and 13C-urea breath test forH. pyloriinfection were performed.Results. Among 5417 subjects who completed questionnaires and 13C-urea breath test, 3435 (63.41%) wereH. pyloripositive. The prevalence reached a peak at the age of 30–39 years (90.82%). There was significant difference between sexes and women had a higher infection rate than men. The prevalence ofH. pyloriinfection was also associated with eating kipper food and fried food. No association betweenH. pyloriprevalence and smoking or drinking was found. Compared to healthy individuals, people with dyspeptic diseases (peptic ulcer, gastroenteritis) presented a high prevalence ofH. pyloriinfection. Using multivariate logistic regression analysis, age and history of peptic ulcer and gastroenteritis were the independent predictors forH. pyloriinfection.Conclusions. Yangzhong city had a high prevalence ofH. pyloriinfection and was related to several risk factors. The underlying mechanisms are needed to be further investigated.

scholarly journals Correlation between Quantitative 13C-Urea Breath Test and Helicobacter pylori Treatment Success in a Population-Based Cohort

2018 ◽  
Vol 2018 ◽  
pp. 1-6 ◽  
Author(s):  
Doron Boltin ◽  
Zohar Levi ◽  
Tsachi Tsadok Perets ◽  
Hemda Schmilovitz-Weiss ◽  
Rachel Gingold-Belfer ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Breath Test ◽  
Treatment Success ◽  
Population Based ◽  
Urea Breath Test ◽  
First Line Therapy ◽  
13C Urea Breath Test ◽  
Helicobacter Pylori Treatment ◽  
H Pylori ◽  
First Time

Background. There are continual efforts to identify factors which influence the success of first-line therapy for Helicobacter pylori (H. pylori) infection. The 13C-urea breath test result (C13-UBT) utilizes H. pylori urease activity and is a highly accurate diagnostic assay. We aimed to determine whether the magnitude of C13-UBT result is related to treatment success. Methods. Adult patients who underwent a first-time 13C-urea breath test between January 2010 and January 2016 were included. In order to isolate a naïve test-and-treat population who were unlikely to have undergone an initial endoscopy-based H. pylori test, we excluded patients > 45 years and those with a previous C13-UBT. Data were extracted from the Clalit Health Services laboratory database. Results. A total of 94,590 subjects (36.1% male, age 28.5 ± 6.0 years) who underwent a first-time C13-UBT during the study period were included. C13-UBT was positive in 48,509 (51.3%) subjects. A confirmatory posttreatment C13-UBT was performed in 18,375 (37.8%), and eradication was successful in 12,018 (65.4%). The mean C13-UBT recording was 20.6 ± 16.2 DOB in subjects with successful eradication and 19.5 ± 13.1 DOB in subjects with treatment failure (OR, 1.01; 95% CI 1.00-1.01, p<0.01). Among patients in the upper quintile of C13-UBT measurement, eradication was achieved in 67.6%, compared to 62.6% in the lower quintile (OR, 1.22; 95% CI 1.11-1.35, p<0.01). Subjects in the top 1 percentile (C13-UBT ≥ 70 DOB) achieved eradication in 75.0%, compared to 65.3% among subjects with C13-UBT < 70 DOB (OR, 1.59; 95% CI 1.05-2.41, p<0.01). Conclusions. The superiority in H. pylori eradication observed in subjects with a higher C13-UBT DOB is small but significant. Further studies should examine the physiological and microbiological basis for this finding.

Positive serology indicates an active H. pylori infection in patients with atrophic gastritis in spite of negative histology and 13C-urea breath test

1998 ◽  
Vol 114 ◽  
pp. A183 ◽  
Author(s):  
A. Kokkola ◽  
P. Puolakkainen ◽  
H. Rautelin ◽  
P. Sipponen ◽  
M. Färkkilä ◽  
...  
Keyword(s):  
Atrophic Gastritis ◽  
Breath Test ◽  
Urea Breath Test ◽  
Positive Serology ◽  
13C Urea Breath Test ◽  
H Pylori

Knowledge of a negative 13C-urea breath test reduces health care utilisation for dyspepsia in a population H pylori test and treat program

2000 ◽  
Vol 118 (4) ◽  
pp. A678
Author(s):  
Paul Moayyedi ◽  
Richard Feltbower ◽  
Sara Duffett ◽  
Will Crocombe ◽  
David Forman ◽  
...  
Keyword(s):  
Health Care ◽  
Breath Test ◽  
Health Care Utilisation ◽  
Urea Breath Test ◽  
Test And Treat ◽  
Care Utilisation ◽  
13C Urea Breath Test ◽  
H Pylori

scholarly journals Helicobacter pyloriEradication with Either Seven-Day or 10-Day Triple Therapies, and with a 10-Day Sequential Regimen

2006 ◽  
Vol 20 (2) ◽  
pp. 113-117 ◽  
Author(s):  
Giuseppe Scaccianoce ◽  
Cesare Hassan ◽  
Alba Panarese ◽  
Donato Piglionica ◽  
Sergio Morini ◽  
...  
Keyword(s):  
Triple Therapy ◽  
Breath Test ◽  
Eradication Rate ◽  
Urea Breath Test ◽  
Cure Rate ◽  
Intention To Treat ◽  
Significant Difference ◽  
Sequential Regimen ◽  
H Pylori ◽  
Very High

BACKGROUND:Helicobacter pylorieradication rates achieved by standard seven-day triple therapies are decreasing in several countries, while a novel 10-day sequential regimen has achieved a very high success rate. A longer 10-day triple therapy, similar to the sequential regimen, was tested to see whether it could achieve a better infection cure rate.METHODS: Patients with nonulcer dyspepsia andH pyloriinfection were randomly assigned to one of the following three therapies: esomeprazole 20 mg, clarithromycin 500 mg and amoxycillin 1 g for seven days or 10 days, or a 10-day sequential regimen including esomeprazole 20 mg plus amoxycillin 1 g for five days and esomeprazole 20 mg, clarithromycin 500 mg and tinidazole 500 mg for the remaining five days. All drugs were given twice daily.H pylorieradication was checked four to six weeks after treatment by using a13C-urea breath test.RESULTS: Overall, 213 patients were enrolled.H pylorieradication was achieved in 75.7% and 77.9%, in 81.7% and 84.1%, and in 94.4% and 97.1% of patients following seven-day or 10-day triple therapy and the 10-day sequential regimen, at intention-to-treat and per protocol analyses, respectively. The eradication rate following the sequential regimen was higher than either seven-day (P=0.002) or 10-day triple therapy (P=0.02), while no significant difference emerged between the latter two regimens (P=0.6).CONCLUSIONS: The 10-day sequential regimen was significantly more effective than both triple regimens, while 10-day triple therapy failed to significantly increase theH pylorieradication rate achieved by the standard seven-day regimen.

Helicobacter pylori eradication can induce platelet recovery in idiopathic thrombocytopenic purpura

Blood ◽  
2001 ◽  
Vol 97 (3) ◽  
pp. 812-814 ◽  
Author(s):  
Giovanni Emilia ◽  
Giuseppe Longo ◽  
Mario Luppi ◽  
Giovanna Gandini ◽  
Monica Morselli ◽  
...  
Keyword(s):  
Idiopathic Thrombocytopenic Purpura ◽  
Breath Test ◽  
Complete Response ◽  
Urea Breath Test ◽  
Thrombocytopenic Purpura ◽  
Platelet Recovery ◽  
Helicobacter Pylori Eradication ◽  
13C Urea Breath Test ◽  
H Pylori ◽  
New Good

Abstract Recent reports have suggested an association betweenHelicobacter pylori infection and idiopathic thrombocytopenic purpura (ITP). The prevalence of H pyloriinfection and the effect of its eradication in a series of 30 ITP patients were investigated. H pylori infection has been documented in 13 patients (43.33%) by 13C urea breath test and confirmed by histologic examination. Bacterium eradication with antibiotics, obtained in 12 of 13 infected patients (92.3%), led to a complete response in 4 (33.33%) and to a partial response (platelets 90 × 109/L-120 × 109/L) in 2 (16.66%). The response was maintained for a median of 8.33 months, but 1 patient relapsed 7 months after eradication. Search for H pyloriinfection seems appropriate in ITP patients at diagnosis. Bacterium eradication provides a new good option for a nonimmunosuppressive treatment in some ITP patients.

scholarly journals PROSPECTIVE STUDY FOR VALIDATION OF A SINGLE PROTOCOL FOR THE 13C-UREA BREATH TEST USING TWO DIFFERENT DEVICES IN THE DIAGNOSIS OF H. PYLORI INFECTION

2019 ◽  
Vol 56 (2) ◽  
pp. 197-201 ◽  
Author(s):  
Luiz Gonzaga Vaz COELHO ◽  
Osmar Reni TRINDADE ◽  
Laiane Alves LEÃO ◽  
Henrique Gomes RIBEIRO ◽  
Izabella Silva FREITAS ◽  
...  
Keyword(s):  
Gold Standard ◽  
Breath Test ◽  
Kappa Coefficient ◽  
Urea Breath Test ◽  
Wilcoxon Test ◽  
Breath Sample ◽  
Prospective Comparison ◽  
Before And After ◽  
13C Urea Breath Test ◽  
H Pylori

ABSTRACT BACKGROUND: 13C-urea breath test (UBT) is the gold-standard, noninvasive method for H. pylori diagnosis. However, there is no uniform standardization of the test. This situation can be unpractical for laboratories running with two or more devices. OBJECTIVE: To perform a prospective comparison validation study of UBT employing one validated protocol for two different devices: BreathID Hp Lab System® (Exalenz Bioscience Ltd, Israel), here called device A and IRIS-Doc2® (Wagner Analysen-Technik, Germany, now Mayoly Spindler Group, France), here called device B, in the diagnosis of H. pylori infection. METHODS: A total of 518 consecutive patients (365 females, 153 males, mean age 53 years) referred for UBT were included. All patients received device A protocol as follow: after at least one hour fasting, patients filled two bags prior to the test, then ingested an aqueous solution containing 75 mg of 13C-urea with a 4.0 g citric acid powder and filled another two bags 15 min after ingesting the test solution. One pair of breath sample bags (before and after ingestion) was analyzed by the two different devices. A delta over baseline (DOB) ≥5‰ indicated H. pylori infection. Statistics: Wilcoxon test, kappa coefficient with 95% CI, Wilson’s method. RESULTS: Considering the device A protocol as the gold standard, its comparison with device B showed a sensitivity of 99.3% (95% CI: 96.3-99.9) and a specificity of 98.9% (95% CI: 97.3-99.6). Kappa coefficient was 0.976 (95% IC: 0.956-0.997). CONCLUSION: Correlation between the two devices was excellent and supports a uniform standardization of UBT.

scholarly journals Risk Factors For Recurrence of Peptic Ulcer Disease: A Retrospective Study In Tertiary Care Referral Center

2022 ◽  
Author(s):  
Yaser Alsinnari ◽  
Mohammed S. Alqarni ◽  
Meshari Attar ◽  
Ziad M. Bukhari ◽  
Faisal Baabbad ◽  
...  
Keyword(s):  
Risk Factors ◽  
Peptic Ulcer ◽  
Peptic Ulcer Disease ◽  
Recurrence Rate ◽  
Univariate Analysis ◽  
Tertiary Care ◽  
Ulcer Disease ◽  
Significant Difference ◽  
Risk Factors For Recurrence ◽  
H Pylori

Abstract Backgrounds: Peptic ulcer disease (PUD) is a common gastrointestinal tract disease characterized by mucosal damage secondary to pepsin and gastric acid secretion. The aim of this study was to evaluate the five-year recurrence rate for treated patients with PUD and risk factors contributing to PUD relapses.Methods: From 2016 through 2021, all patients with endoscopy-proved PUD were identified by reviewing medical records (Best-Care system). Possible risk factors including smoking, non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, alcohol, caffeine, and steroid were analyzed by univariate analysis. Treatment outcomes, 5-year recurrence rate, and mortality rate were assessed.Results: Among 223 patients, there were 187 (83.8%), who diagnosed endoscopy-proved PUD and 36 (16.2%), who diagnosed clinical PUD. Among them, 126 (56.5%) patients were males and the mean age was 62±2 years. The five years recurrence rate of PUD was 30.9%. There was no significant difference in the recurrence rate between the duodenal ulcer (33.3%) and the gastric ulcer (28.8%). By univariate analysis, the use of steroid and NSAID and H. pylori infection were potential risk factors for PUD (P < 0.005). The common complication of PUD was gastrointestinal bleeding (34.1%). Patients who had a complicated PUD were associated with a higher rate of recurrence (45.9%) compared to the uncomplicated PUD (19.2%) (P > 0.05). Conclusion: Our findings demonstrated that the five years recurrence rate of PUD was 30.9%. The use of steroid and NSAID and H. pylori infection were risk factors for recurrence of PUD. PUD places a significant burden on health care systems. Therefore, a multicenter prospective study is needed for effective management to prevent recurrence and complications of PUD.

Sign in / Sign up

Export Citation Format

Share Document